Cargando…
What is new in BTS 2017 & ATS/ERS/ESCMID/IDSA 2020 guidelines on treatment of non-tuberculous mycobacterial pulmonary disease?
Autores principales: | Sharma, Surendra Kumar, Upadhyay, Vishwanath, Mohan, Alladi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9131807/ https://www.ncbi.nlm.nih.gov/pubmed/35345066 http://dx.doi.org/10.4103/ijmr.ijmr_2573_21 |
Ejemplares similares
-
Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline
por: Nahid, Payam, et al.
Publicado: (2019) -
Erratum: Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline
Publicado: (2020) -
ATS/CDC/ERS/IDSA Clinical Practice Guidelines for Treatment of Drug-Resistant Tuberculosis: A Two-edged Sword?
por: Chang, Kwok-Chiu, et al.
Publicado: (2020) -
Epidemiology, diagnosis & treatment of non-tuberculous mycobacterial diseases
por: Sharma, Surendra K., et al.
Publicado: (2020) -
Cost effectiveness of adherence to IDSA/ATS guidelines in elderly patients hospitalized for Community-Aquired Pneumonia
por: Egger, Michael E., et al.
Publicado: (2016)